Document Detail

Proteasome inhibition prolongs survival during lethal hemorrhagic shock in rats.
MedLine Citation:
PMID:  23354244     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Several lines of evidence suggest that proteasomes, the major nonlysosomal proteases in eukaryotes, are involved in the pathophysiology of various disease processes, including ischemia-reperfusion injury and trauma. Recently, we demonstrated that 26S proteasome activity is negatively regulated by adenosine triphosphate (ATP) and that proteasome activation during ischemia contributes to myocardial injury. The regulation of tissue proteasome activity by ATP and the potential of proteasomes as drug targets during hemorrhagic shock, however, are unknown. Thus, we evaluated the regulation of tissue proteasome peptidase activity and the effects of the proteasome inhibitor bortezomib in rat models of hemorrhagic shock.
METHODS: Series 1 includes animals (n = 20) hemorrhaged to a mean arterial blood pressure of 30 mm Hg for up to 45 minutes. Series 2 includes animals hemorrhaged to a mean arterial blood pressure of 30 mm Hg for 30 minutes, followed by bortezomib (0.4 mg/kg) or vehicle administration (n =5 per group) and fluid resuscitation until 75 minutes. Series 3 includes animals that underwent 40% blood volume hemorrhage, followed by 2% blood volume hemorrhage every 15 minutes until death. Bortezomib (0.4 mg/kg) or vehicle were administered 15 minutes after the onset of hemorrhage (n = 6-7 per group). Vital signs were continuously monitored. The heart, lung, and pectoral muscle were analyzed for proteasome peptidase activities and levels of ATP, ubiquitin-protein conjugates, and cytokines (tumor necrosis factor α, interleukin 6, and interleukin 10).
RESULTS: In Series 1, proteasome peptidase activities in tissue extracts increased proportional to the decrease in tissue ATP concentrations during hemorrhagic shock. Activation of proteasome peptidase activity with decreases of the ATP assay concentration was also detectable in normal tissue extracts. In Series 2, systemic administration of bortezomib inhibited tissue proteasome activities but did not affect the physiologic response. In Series 3, bortezomib inhibited tissue proteasome activities, increased endogenous ubiquitin-protein conjugates, and prolonged survival time from treatment from 48.5 minutes in the control group to 85 minutes (p = 0.0012). Bortezomib treatment did not affect tissue cytokine levels.
CONCLUSION: Proteasome activation contributes to the pathophysiology of severe hemorrhagic shock. Pharmacologic inhibition of the proteasome may provide a survival advantage during lethal hemorrhagic shock.
Harold H Bach; Heather M Laporte; Yee M Wong; Richard L Gamelli; Matthias Majetschak
Related Documents :
9497114 - The functional outcome of shunting h-tx rat pups at different ages.
23751804 - Therapeutic option for managing lung injury induced by infrarenal aortic cross-clamping.
1594674 - Behavioral heterogeneity in sprague-dawley rats.
3398824 - Detection limits of different approaches in behavioral teratology, and correlation of e...
16845214 - Protective effects of early administration of alpha-lipoic acid against lipopolysacchar...
8039844 - Role of angiotensin ii in renal injury of deoxycorticosterone acetate-salt hypertensive...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The journal of trauma and acute care surgery     Volume:  74     ISSN:  2163-0763     ISO Abbreviation:  J Trauma Acute Care Surg     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-28     Completed Date:  2013-04-05     Revised Date:  2014-10-12    
Medline Journal Info:
Nlm Unique ID:  101570622     Medline TA:  J Trauma Acute Care Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  499-507     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenosine Triphosphate / analysis,  physiology
Blotting, Western
Boronic Acids / therapeutic use*
Disease Models, Animal
Enzyme-Linked Immunosorbent Assay
Proteasome Endopeptidase Complex / drug effects*,  physiology
Proteasome Inhibitors / therapeutic use*
Pyrazines / therapeutic use*
Rats, Inbred Lew
Shock, Hemorrhagic / drug therapy*,  mortality,  physiopathology
Grant Support
Reg. No./Substance:
0/Boronic Acids; 0/Proteasome Inhibitors; 0/Pyrazines; 0/bortezomib; 8L70Q75FXE/Adenosine Triphosphate; EC Endopeptidase Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inflammatory and apoptotic alterations in serum and injured tissue after experimental polytrauma in ...
Next Document:  Microvascular endothelial cell hyperpermeability induced by endogenous caspase 3 activator staurospo...